Immune responses to a recombinant Rv0057-Rv1352 fusion protein of Mycobacterium tuberculosis.
The identification and characterization of antigens of Mycobacterium tuberculosis help in understanding the mechanisms of protective immunity and in improving diagnostic methods for TB. Rv0057 and Rv1352 proteins are new T-cell antigens, found to play roles in TB infection. In this study, a recombinant fusion protein Rv0057-Rv1352 was made and analyzed for its immunological characteristics and potential utility. It showed good immunoreactivity with serum from TB patients by western blotting. The antibody levels against Rv0057-Rv1352 were significantly higher in sera from 69 TB patients than in sera from 60 patients with non-TB respiratory diseases (P<0.001). The sensitivities of a diagnostic ELISA test based on detecting Rv0057-Rv1352 antibody (60.3%) or 38 kDa-16 kDa antibody (58.8%) were comparable to commercial rapid test B (75.4%), and significantly higher (p<0.001) than bacteriological methods (15.9%), rapid test A (20.3%), or rapid test C (29.0%). The specificities of Rv0057-Rv1352 (93.3%) or 38 kDa-16 kDa antibody tests (93.3%) were equivalent to the rapid tests A (93.3%) and C (86.7%), and significantly higher than rapid test B (63.3%, p<0.001). When 38 kDa-16 kDa was used together with Rv0057-Rv1352, the test sensitivity reached 85.5%, and its specificity remained high (86.7%). The test was as sensitive with bacterium-positive TB patients as with bacterium-negative. In an ELISPOT assay for cellular immunity, Rv0057-Rv1352 stimulated T lymphocytes to produce fewer spots secreting IFN-γ than CFP10-ESAT6 fusion protein did (p>0.05). These results suggest that Rv0057-Rv1352 has potential for the serodiagnosis of active pulmonary TB.